CL2023001460A1 - Inhibidor de la progresión de la fibrosis - Google Patents

Inhibidor de la progresión de la fibrosis

Info

Publication number
CL2023001460A1
CL2023001460A1 CL2023001460A CL2023001460A CL2023001460A1 CL 2023001460 A1 CL2023001460 A1 CL 2023001460A1 CL 2023001460 A CL2023001460 A CL 2023001460A CL 2023001460 A CL2023001460 A CL 2023001460A CL 2023001460 A1 CL2023001460 A1 CL 2023001460A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
receptor
antibody
fibrosis
progression
Prior art date
Application number
CL2023001460A
Other languages
English (en)
Spanish (es)
Inventor
Yoshizaki Ayumi
Kuzumi Ai
Sato Shinichi
Fujita Tomoyuki
Watanabe Hideki
Original Assignee
Maruho Kk
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruho Kk, Univ Tokyo filed Critical Maruho Kk
Publication of CL2023001460A1 publication Critical patent/CL2023001460A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2023001460A 2020-11-30 2023-05-22 Inhibidor de la progresión de la fibrosis CL2023001460A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2020/044406 WO2022113316A1 (ja) 2020-11-30 2020-11-30 線維化の進行抑制剤

Publications (1)

Publication Number Publication Date
CL2023001460A1 true CL2023001460A1 (es) 2023-12-01

Family

ID=81754505

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001460A CL2023001460A1 (es) 2020-11-30 2023-05-22 Inhibidor de la progresión de la fibrosis

Country Status (12)

Country Link
US (1) US20240084020A1 (https=)
EP (1) EP4252771A4 (https=)
JP (3) JPWO2022113316A1 (https=)
KR (1) KR20230114698A (https=)
CN (1) CN116829187A (https=)
AU (1) AU2021385871A1 (https=)
CA (1) CA3199351A1 (https=)
CL (1) CL2023001460A1 (https=)
IL (1) IL303159A (https=)
MX (1) MX2023006164A (https=)
TW (1) TW202237182A (https=)
WO (2) WO2022113316A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) * 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物

Also Published As

Publication number Publication date
KR20230114698A (ko) 2023-08-01
EP4252771A4 (en) 2024-10-23
JP2022095913A (ja) 2022-06-28
CA3199351A1 (en) 2022-06-02
TW202237182A (zh) 2022-10-01
MX2023006164A (es) 2023-07-28
WO2022114165A1 (ja) 2022-06-02
CN116829187A (zh) 2023-09-29
IL303159A (en) 2023-07-01
JPWO2022114165A1 (https=) 2022-06-02
WO2022113316A1 (ja) 2022-06-02
US20240084020A1 (en) 2024-03-14
AU2021385871A9 (en) 2024-05-02
JP7802601B2 (ja) 2026-01-20
AU2021385871A1 (en) 2023-06-22
JPWO2022113316A1 (https=) 2022-06-02
EP4252771A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
CL2023001460A1 (es) Inhibidor de la progresión de la fibrosis
DOP2018000085A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de actuación sistémica y sus usos
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2011002302A1 (es) Uso de una composicion que comprende un monocaprina y un diluyente farmaceuticamente aceptable para el tratamiento de una condicion micotica causada por trichophyton rubrum tal como tinea pedis, tinea crusis, dermatofitosis y onicomicosis.
BR112022011892A2 (pt) Composições farmacêuticas intranasais de inibidores de cgrp
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX379984B (es) Reducción de la sensación de picazón en la piel.
MX2019001534A (es) Composiciones para el cuidado bucal.
BR112015020707A2 (pt) formulações transdermicas
PE20142140A1 (es) Composiciones similares a azeotropos de z-1,1,1,4,4,4-hexafluoro-2-buteno y e-1,1,1,4,4,4-hexafluoro-2-buteno y usos de estos
MX2017016774A (es) Agente terapeutico para la fibrosis.
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
MX2019009922A (es) Formulaciones a base de aceite para suministro sublingual y bucal.
CL2020000551A1 (es) Formulación de uso tópico para el control y la prevención de parásitos en animales.
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
PE20180026A1 (es) Composicion topica curativa
MX376496B (es) Agente protector para queratoconjuntiva o agente supresor para el trastorno queratoconjuntival.
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
DOP2022000222A (es) Formulación estable
PE20140590A1 (es) Uso de un agente quelante y compuestos antimicrobianos de peptido
MX2022003830A (es) Compuesto de n-(1h-imidazol-2-il)benzamida y composicion farmaceutica que comprende el mismo como ingrediente activo.
JOP20170148A1 (ar) مثبطات Wnt لعلاج التليف
PE20150755A1 (es) Formulacion transdermica que contiene inhibidores de cox
ECSP22058286A (es) Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónico
MX2025008705A (es) Sistema para el suministro oral de un ingrediente activo